This review summarizes the molecular mechanisms of right ventricular fibrosis in response to pressure overload and overviews preclinical and clinical studies targeting it to improve cardiac function.
This review provides an overview of the molecular mechanisms driving right ventricular fibrosis in pulmonary hypertension and summarizes studies targeting these pathways to improve cardiac function.
Right ventricular fibrosis is a stress response, predominantly mediated by cardiac fibroblasts. This cell population is sensitive to increased levels of pro-inflammatory cytokines, pro-fibrotic growth factors and mechanical stimulation. Activation of fibroblasts results in the induction of various molecular signaling pathways, most notably the mitogen-activated protein kinase cassettes, leading to increased synthesis and remodeling of the extracellular matrix. While fibrosis confers structural protection in response to damage induced by ischemia or (pressure and volume) overload, it simultaneously contributes to increased myocardial stiffness and right ventricular dysfunction. Here, we review state-of-the-art knowledge of the development of right ventricular fibrosis in response to pressure overload and provide an overview of all published preclinical and clinical studies in which right ventricular fibrosis was targeted to improve cardiac function.
Bekedam et al. (Mon,) conducted a review in Right ventricular fibrosis in pulmonary hypertension. This review summarizes the molecular mechanisms of right ventricular fibrosis in response to pressure overload and overviews preclinical and clinical studies targeting it to improve cardiac function.